SCIENTIFIC EVIDENCE

Tumor-associated macrophages promote chemoresistance to Paclitaxel via activating NOTCH2-JAG1 juxtacrine signaling.

Molecular cancer
Yu F, Zhou Q, Yu W, Zhou T, Cao C, Xie Y, Zhang P, Liu H, He W, Cheng A, Ma X, Wu Q, Zhao Q, Guo J, Zhang K, Zhou Y, Shi J, Yang Z.

Publication Overview

Key findings, Countstar context, and access to the original paper.
2026
Cancer Research
Immunology
No items found.
Key Finding
The findings suggest NOTCH2 is a viable biomarker for paclitaxel resistance and that combining NOTCH2 inhibitor with taxane is an effective therapeutic strategy to selectively disrupt tumor-macrophage interaction and overcome macrophage-mediated taxane resistance in NOTCH2-positive tumors.
Countstar Connection
Researchers used Countstar (model not specified) to assess cell numbers in the study's cell samples before downstream analysis in the 2026 Molecular cancer study.
View paper ↗
Stay Connected toCountstar Science
Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.
Meet us online
Products
About Us
Contact
© 2026 Countstar. All rights reserved.